Zoetis Inc. (ZTS)
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Profile
Zoetis Inc.
- Exchange
- NYSE
- Ticker
- ZTS
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- US
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Key facts
Zoetis Inc.: key facts
- Zoetis Inc. (NYSE: ZTS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector.
- In fiscal 2025, Zoetis Inc. reported revenue of $9.5B and net income of $2.7B.
- Revenue grew 5.0% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $9.5B and net income was $2.6B.
MonkScore
Zoetis Inc.'s MonkScore
MonkScore
MonkScore range: 80–90
as of October 2026
Sector rank: 104 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth80–90
- Profitability80–90
- Quality70–80
- Market Conviction70–80
- Safety30–40
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Zoetis Inc.'s annual figures and the last twelve months, in USD. Last report: 30 June 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $9.5B | $9.5B | $9.3B | $8.5B | $8.1B | $7.8B |
| Gross profit | $6.7B | $6.7B | $6.4B | $5.8B | $5.5B | $5.3B |
| Operating income | $3.5B | $3.6B | $3.4B | $3.1B | $2.9B | $2.8B |
| Net income | $2.6B | $2.7B | $2.5B | $2.3B | $2.1B | $2.0B |
| Operating cash flow | $2.9B | $2.9B | $3.0B | $2.4B | $1.9B | $2.2B |
| Capital expenditure | -$521.0M | -$621.0M | -$655.0M | -$732.0M | -$586.0M | -$477.0M |
| Free cash flow | $2.4B | $2.3B | $2.3B | $1.6B | $1.3B | $1.7B |
| Total debt | $9.2B | $9.5B | $6.7B | $6.8B | $8.1B | $6.7B |
| Cash | $1.5B | $2.3B | $2.0B | $2.0B | $3.6B | $3.5B |
Revenue growth a year
- 1-year
- 2.3%
- 3-year
- 5.4%
- 4-year
- 5.0%
Compound growth between fiscal years.
Peers
Similar companies
- Ironwood Pharmaceuticals, Inc.NASDAQ:IRWDMonkScore range: 90–100
- Lantheus Holdings, Inc.NASDAQ:LNTHMonkScore range: 90–100
- Eton Pharmaceuticals, Inc.NASDAQ:ETONMonkScore range: 90–100
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.